Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Must satisfy A and B and C below:~A. Women aged 45+~B. Postmenopausal~C. Osteoporotic with high risk of fracture~Exclusion Criteria:~* History of significant hepatic, renal, cardiovascular, malignant disease, or conditions with impaired immune system~* Current alcohol or substance abuse~* Major psychiatric disorders~* Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia~* Known congenital or acquired bone disease other than osteoporosis~* Current use or past use in the past 12 months of oral bisphosphonates~* Current use or use in the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin~* Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months~* Any current or previous use of strontium or intravenous bisphosphonates~* Sensitivity to cell-derived drug products or teriparatide~* Extensive dental work involving dental extraction or dental implant within the past 2 months or in the upcoming 2 months~* Inability to sit upright for 30 minutes~* Esophageal abnormalities

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Denosumab 60mg subcutaneous injection (Type: ACTIVE_COMPARATOR): Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
- Alendronate 70mg weekly x 8 weeks (Type: ACTIVE_COMPARATOR): Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).